RxDoctor Payments Data

David Wu, MD

Urology · Bloomfield, NJNPI 1871533844

Payments from drug & device makers

$4,991in general payments, 2019–2025

Across 270 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$792
  • Astellas Pharma US Inc$578
  • AbbVie$420
  • Johnson & Johnson$350
  • Dendreon Pharmaceuticals LLC$312
  • Sumitomo Pharma America, Inc.$302
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,74795%
  • Education$2445%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,991 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$128,871
Medicare patients
265
Services billed
2,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide15$240,393
Lupron DepotLeuprolide Acetate18$123,981
MyrbetriqMirabegron157$99,486
GemtesaVibegron83$71,850
Tamsulosin Hcl637$8,086
Solifenacin Succinate64$3,314
Silodosin20$3,160
Oxybutynin Chloride ErOxybutynin Chloride112$3,040
Finasteride229$2,200
Dutasteride40$1,845
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$968
Doxycycline Hyclate104$724
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip36$706
Testosterone12$403
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav72$342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$578$339,879172 claims
AbbVieLupron Depot$420$123,98118 claims
Sumitomo Pharma America, Inc.Gemtesa$302$71,85083 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.

Other urology in Bloomfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →